Chiao Lo - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Chiao Lo

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

Oncotarget|July 3, 2018

ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancerKarineh Petrossian, Noriko Kanaya, Chiao Lo, et al.

Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 25, 2022

Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-respondersPo-Han Lin, Ling-Ming Tseng, Yi-Hsuan Lee, et al.

Breast Cancer Research and Treatment|February 3, 2022

Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patientsPo-Han Lin, Shin-Cheh Chen, Ling-Ming Tseng, et al.

Pageof 5

Search research articles

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

Oncotarget|July 3, 2018

ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancerKarineh Petrossian, Noriko Kanaya, Chiao Lo, et al.

Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 25, 2022

Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-respondersPo-Han Lin, Ling-Ming Tseng, Yi-Hsuan Lee, et al.

Breast Cancer Research and Treatment|February 3, 2022

Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patientsPo-Han Lin, Shin-Cheh Chen, Ling-Ming Tseng, et al.

Pageof 5